More Than Half of Topline Revenue Disappears: The Gross-to-Net Reality
During Merck’s 2022 earnings call, management sped past a figure that, to anyone outside pharmaceutical finance, lands somewhere between shocking and totally opaque: $14.3 billion in gross-to-net deductions, erasing 51% of the company’s recorded US pharma sales. Merck isn’t an outlier here. Across the sector, the gulf between the sticker price of branded drugs and the revenue manufacturers ultimately collect, the infamous net sales gap, continues to stretch wider. Anyone following pharma performance or drug pricing trends ignores this gap at their peril. That’s not hyperbole; it’s just how the math works now.
“Gross-to-net” covers a mix of discounts, rebates, copay assistance, chargebacks, returns, and fees, basically everything slicing away at the shiny top-line list price until all that’s left is real-world revenue. The higher a drug’s list price, the more dramatic the deductions become. With pressure from PBM formularies and government price restrictions, this is now a defining characteristic for blockbusters. Take insulin: for years, gross-to-net discounts there have blown past 70%. A $500 million quarterly franchise? Maybe $140 to $200 million of that actually hits the books.
Pharma rarely spells out gross-to-net figures for individual products, so investors are left piecing things together from segment results, SEC filings, and outside datasets from RxInfo.ai or RxPBM.ai. In all those footnotes and secondary tables, the truth is clear enough: the list price is something of an illusion. Actual revenue hangs on what’s hammered out with PBMs and government buyers months after the sale.
Peeling Back the Mechanism: PBMs, Rebates, and Mandates at Work
Think of the list price as a sticker slapped on the box, really just a starting gun for negotiations that end up dominated by PBMs and federal programs. Why inflate list prices? Simple, manufacturers use them to secure access. When they offer steeper rebates, their products are more likely to score top spots on PBM formularies. PBMs, always looking to capture a bigger share of these rebates, squeeze for higher sticker prices and even deeper discounts. It’s a loop: as list prices spiral up, actual net prices remain flat, or in some cases, slip lower.
Humira provides a clear lesson. AbbVie pulled in over $20 billion in final-year Humira sales under patent protection, but SEC filings reveal that 45-55% of US list revenue vanished to gross-to-net deductions. After accounting for PBM rebates and Medicare “best price” rules, the economic reality was far less impressive than any top-line figure. New specialty drugs sometimes start with lower gross-to-net deductions, 10-20% in the earliest quarters. That rarely lasts. Once PBMs ramp up and Medicare Part D coverage expands, those deductions can easily double, even triple.
But there’s more. Medicaid and the 340B drug discount program layer on extra complications. Medicaid’s “best price” rule? If a manufacturer hands a deep rebate to any commercial payer, that new price passes to Medicaid too, raising the stakes for every deal struck. Meanwhile, 340B can force discounts so steep that certain hospital-administered drugs dip below cost of goods sold. Any talk of list price on its own, frankly, is close to useless.
Gross-to-Net’s Impact on Valuation, Why This Metric Can’t Be Ignored
Reading through pharma earnings, I’ve seen gross-to-net morph from a fine-print curiosity to a core driver of earnings quality. It separates what looks like steady growth from the reality underneath. Say a specialty drug clocks $1 billion in annual list sales and faces a 60% gross-to-net deduction. Net revenue? Just $400 million. If rebates or 340B participation jump next year, even flat list sales can yield sharply lower real revenue.
Valuation can turn on these numbers. Multiples tied to gross sales paint a rosier story than those based on net revenue, especially as gross-to-net creeps upward each reporting cycle. For specialty pharmacies and providers, profits rise and fall with the actual net price, never the list price. When a manufacturer tweaks copay assistance or adds new rebates, pharmacy margins can get squeezed almost overnight. And if a plan moves a drug to a higher cost-sharing tier, the response is predictable: more rebates, less net revenue, suddenly thinner margins everywhere down the line.
So pay attention when management references “gross-to-net erosion”, especially for brands facing biosimilar or generic threats. The list price may look fine in headlines, but the underlying net revenue can rapidly deteriorate. In major franchises, we’ve seen this story repeat: gross sales look healthy, net revenue tanks as rebate demands surge. (Honestly, it can be faintly comical to see the PR spin versus what the numbers actually reveal.)
Practical Analyst Moves: How to Catch the Signals and Spot the Trouble
The smart money knows the drill: start with SEC footnotes and segment results. That’s where gross-to-net details sometimes surface, even if tucked away. Watch for direct guidance (often only hinted at in Q&A sessions), sudden spikes in “contractual allowances,” or outsized “rebates and chargebacks” listed on the income statement. Companies leaning heavily on copay cards? They’ll see short-term gross-to-net shifts whenever insurers crank up deductibles or coinsurance.
For an external reality check, blend those disclosures with claims-level data from RxInfo.ai and RxPBM.ai. These sources can flag sharp changes in net prices. That’s essential in categories where PBM deals churn quickly, or when new therapies launch with fanfare but little transparency on true net revenue.
Here’s the bottom line: the widening gross-to-net gap sits at the heart of US drug pricing and explains why both sides of the debate feel justified. Policymakers point to soaring list prices as evidence of a broken system. Industry counters with net revenue data, arguing much of the sticker shock is an accounting myth. Both camps have a piece of the truth, but not the whole picture. For anyone serious about drug economics, investors, buyers, policy watchers, forget the sticker. Follow the money, after rebates. That’s where the story really is.
